Denmark's Novo Nordisk has agreed to pay $70 million ... semaglutide in phase 3 in combination with drugs from Gilead, a long-acting FGF21 analogue in phase 2, and early-stage candidates partnered ...

Telehealth company Hims & Hers stirred up controversy by debuting a 2025 Super Bowl ad touting the benefits of its ...

Novo Nordisk boasts 45 million customers using their drug Ozempic, which has caused a revolution in weight-loss treatment. Never before was there a drug that actually worked for weight loss.

Novo Nordisk and Eli Lilly have asked the federal government to list their blockbuster weight-loss drugs on the Pharmaceutical Benefits Scheme, arguing funding the treatment will reduce a costly ...

In this video, I will go over Novo Nordisk's (NVO-3.62%) and Eli Lilly's recent earnings report. Watch the short video to learn more, consider subscribing, and click the special offer link below.

In this article, we are going to take a look at where Novo Nordisk A/S (NYSE ... 20% following clinical trial results for its obesity drug, CagriSema. The trial showed a weight reduction of ...

The new oral drug is viewed as a key product for Novo Nordisk as it tries to case Eli Lilly's Trulicity (dulaglutide), a once-weekly GLP-1 drug that is the market leader in the class with sales of ...

Trading in Novo Nordisk shares by board members ... expand to enable the discovery and development of up to 20 novel drug programmes in obesity, type 2 diabetes, and cardiovascular diseaseExpanded ...

Next-generation obesity drugs will work differently from Ozempic and Wegovy — aiming to deliver greater weight loss with ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...